Form 4: Compass Therapeutics Director Acquires Stock Options

Mary Ann Gray, a director at Compass Therapeutics, acquired stock options for 40,000 shares at an exercise price of $3.65 on February 11, 2025.

Summary

• On February 11, 2025, Mary Ann Gray, a director of Compass Therapeutics, Inc. (CMPX), acquired stock options.
• The options grant the right to buy 40,000 shares of Compass Therapeutics common stock at an exercise price of $3.65 per share.
• The options vest in 48 substantially equal monthly installments beginning on March 11, 2025.
• The options expire on February 11, 2035.
• Following the transaction, Ms. Gray directly owns options for 40,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director acquiring stock options suggests confidence in the company, but it's a routine transaction.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the biotechnology industry, often used to incentivize performance and align interests with shareholders.
• The vesting schedule of 48 months is a typical vesting period for stock options.
• The exercise price is set at $3.65, which may be related to the current market price of CMPX shares at the time of the grant.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates